相似文献
1
Validity of composite end points in clinical trials.
BMJ. 2005 Mar 12;330(7491):594-6. doi: 10.1136/bmj.330.7491.594.
2
How should clinicians interpret results reflecting the effect of an intervention on composite end points?
Evid Based Med. 2007 Jun;12(3):92. doi: 10.1136/ebm.12.3.92.
3
Key issues in end point selection for heart failure trials: composite end points.
J Card Fail. 2005 Oct;11(8):567-75. doi: 10.1016/j.cardfail.2005.08.350.
4
Are all end points created equal? The case for weighting.
J Am Coll Cardiol. 2011 Feb 1;57(5):546-8. doi: 10.1016/j.jacc.2010.10.014.
5
Measurement of end points in heart failure trials: jousting at windmills?
Mt Sinai J Med. 2004 Oct;71(5):298-304.
6
The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention.
J Am Coll Cardiol. 2008 Feb 19;51(7):701-7. doi: 10.1016/j.jacc.2007.10.034.
7
Composite and surrogate outcomes in randomised controlled trials.
BMJ. 2007 Apr 14;334(7597):756-7. doi: 10.1136/bmj.39176.461227.80.
8
How should clinicians interpret results reflecting the effect of an intervention on composite endpoints: should I dump this lump?
ACP J Club. 2005 Nov-Dec;143(3):A8.
9
Pitfalls of using composite primary end points in the presence of competing risks.
J Clin Oncol. 2010 Oct 1;28(28):4297-9. doi: 10.1200/JCO.2010.30.2802. Epub 2010 Aug 16.
10
Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
J Biopharm Stat. 2011 Jul;21(4):610-34. doi: 10.1080/10543406.2011.551327.
引用本文的文献
1
Prevalence of bias attributable to composite outcome in clinical trials published in 2019-2020: a systematic review.
Rev Bras Epidemiol. 2025 Jun 27;28:e250035. doi: 10.1590/1980-549720250035. eCollection 2025.
2
Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials.
Dermatol Ther (Heidelb). 2025 Jun;15(6):1441-1453. doi: 10.1007/s13555-025-01418-x. Epub 2025 Apr 24.
3
Severe maternal morbidity in the high income setting: a systematic review of composite definitions.
EClinicalMedicine. 2025 Feb 13;81:103105. doi: 10.1016/j.eclinm.2025.103105. eCollection 2025 Mar.
4
Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases.
J Clin Med. 2024 Sep 18;13(18):5512. doi: 10.3390/jcm13185512.
5
Methodology for the selection and evaluation of outcomes for Chinese herbal injection in acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a comprehensive study.
Ann Med. 2024 Dec;56(1):2396567. doi: 10.1080/07853890.2024.2396567. Epub 2024 Sep 10.
6
Composite end points and competing risks analysis.
Interdiscip Cardiovasc Thorac Surg. 2024 Jul 3;39(1). doi: 10.1093/icvts/ivae126.
7
Composite to Clarity: Shifting From Combined to Individual Endpoints in Meta-Analyses of Cardiovascular Outcome Trials.
JACC Adv. 2023 Aug 6;2(7):100548. doi: 10.1016/j.jacadv.2023.100548. eCollection 2023 Sep.
8
The times are changing: A primer on novel clinical trial designs and endpoints in critical care research.
Am J Health Syst Pharm. 2024 Sep 9;81(18):890-902. doi: 10.1093/ajhp/zxae134.
9
Influence of lack of blinding on the estimation of medication-related harms: a retrospective cohort study of randomized controlled trials.
BMC Med. 2024 Mar 7;22(1):83. doi: 10.1186/s12916-024-03300-7.
10
Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?
Front Microbiol. 2023 Oct 19;14:1250483. doi: 10.3389/fmicb.2023.1250483. eCollection 2023.
本文引用的文献
1
Composite outcomes in randomized trials: greater precision but with greater uncertainty?
JAMA. 2003 May 21;289(19):2554-9. doi: 10.1001/jama.289.19.2554.
2
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3.
3
Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial.
Lancet. 2001 Sep 22;358(9286):951-7. doi: 10.1016/S0140-6736(01)06100-1.
4
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
N Engl J Med. 2000 Jan 20;342(3):145-53. doi: 10.1056/NEJM200001203420301.
5
Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators.
Lancet. 1999 Jun 26;353(9171):2179-84. doi: 10.1016/s0140-6736(99)05388-x.
6
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
N Engl J Med. 1999 Jun 24;340(25):1941-7. doi: 10.1056/NEJM199906243402502.
7
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3.
Zotero 插件